PepGen's $117.2M Cash Position, Narrowed Loss, and DSMB Nod for Top Dose in DM1 Trial
PEPG has more than doubled off its 52-week low of $1.01.
Summary
PepGen's Q2 2026 filing shows a reduced net loss and a cash position of $117.2 million, providing runway into late 2027. The DSMB cleared the lead DM1 drug to advance to the highest dose, with pivotal data due in November.
Key Events · Earnings and Guidance · PEPG
-
Cash Runway Extended to Q4 2027
Cash, equivalents, and marketable securities totaled $117.2 million as of June 30, 2026, down from $148.5 million at year-end 2025. Management expects this to fund operations into the fourth quarter of 2027.
-
Net Loss Narrows on Lower R&D Spend
Net loss for Q2 2026 was $17.8 million, compared to $23.1 million in Q2 2025. Research and development expenses fell to $12.5 million from $18.4 million, primarily due to the wind-down of the DMD program and reduced manufacturing activity.
-
DSMB Clears Highest Dose in FREEDOM2 Trial
An independent safety board recommended advancing PGN-EDODM1 to the 12.5 mg/kg cohort — the highest planned dose — in the Phase 2 DM1 trial. Data from the 10 mg/kg cohort is expected in November 2026.
-
Partial Clinical Hold in U.S. Remains Unresolved
The FREEDOM2 study is still on partial clinical hold in the United States. The company continues to work with the FDA to address questions, with no timeline for resolution provided.
Analysis · PEPG · Life Sciences
PepGen's cash runway extends into Q4 2027, but the burn rate remains high — $34.2 million used in operations during the first half of 2026. The independent safety board's clearance to escalate to the highest planned dose in the FREEDOM2 trial is a critical de-risking event ahead of pivotal data in November. However, the unresolved U.S. partial clinical hold and the need for substantial additional capital before commercialization keep the risk elevated.
At the time of this filing, PEPG was trading at $2.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $137M. The 52-week trading range was $1.01 to $7.80. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.